Posted by Michael Wonder on 04 Apr 2022
Acer Therapeutics’ Edsivo (celiprolol) granted FDA breakthrough therapy designation for vascular Ehlers-Danlos syndrome
4 April 2022 - Discussions on-going with FDA through special protocol assessment seeking agreement on planned pivotal Phase 3 DiSCOVER trial with initiation planned by end of Q2 2022.
Acer Therapeutics today announced the U.S. FDA has granted celiprolol breakthrough therapy designation in the U.S. for the treatment of patients with COL3A1 positive vascular Ehlers-Danlos syndrome.
